Singapore scientists from the Institute of Molecular and Cellular Biology explained the successful consequences of the second stage of testing the innovative drug PRL3-Zumab for the treatment of aggressive cancer forms. The study was published scientifically magazine Cell reports medicine (CRM).
PRL3-Zumab is a humanized antibody for 80% of solid (solid) tumors, but not in healthy tissues.
The innovation of the approach lies in the ability to recognize this intracellular protein when the drug appears on the surface of the cancer cells. This allows the immune system to identify and destroy malignant cells through antibody -related cytotoxicity and phagocytosis.
51 patients with various neglected tumors participated in the study. It was particularly impressive in the case of a patient with stomach cancer that observed the stabilization of the disease for 13 months against the background of the PRL3-Zumab treatment. For comparison, progress with standard treatment usually occurs within two months.
The drug showed a suitable safety profile – there was no serious side effect.
Parallel studies in Malaysia and China also showed a decrease in tumors, but full results will only be published next year.
EARLY IN Russia Created Software for early cancer diagnosis.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.